{"id":"W2510046238","doi":"10.1212/wnl.86.16_supplement.pl02.004","title":"Ocrelizumab No Evidence of Disease Activity (NEDA) Status at 96 Weeks in Patients with Relapsing Multiple Sclerosis: Analysis of the Phase III Double-Blind, Double-Dummy, Interferon beta-1a-Controlled OPERA I and OPERA II Studies (PL02.004)","year":2016,"lang":"en","type":"article","venue":"Neurology","topic":"Multiple Sclerosis Research Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"Montreal Neurological Institute and Hospital; NeuroRx Research (Canada); McGill University; University of British Columbia","funders":"","keywords":"Ocrelizumab; Multiple sclerosis; Medicine; Interferon beta; Interferon beta-1a; Internal medicine; BETA (programming language); Double blind; Disease; Oncology; Immunology; Pathology; Alternative medicine; Placebo","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.003906226,0.001186804,0.002348045,0.0003566213,0.00033361,0.000885956,0.000579659,0.001030245,0.001478903],"category_scores_gemma":[0.00216775,0.0005716035,0.00211657,0.0003816663,0.0009085693,0.0007969497,0.0004107207,0.002368425,0.0002947845],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005805635,"about_ca_system_score_gemma":0.0007844525,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004287631,"about_ca_topic_score_gemma":0.0007243663,"domain_scores_codex":[0.9989861,0.000579207,0.00008540982,0.0001637769,0.00008302001,0.0001025681],"domain_scores_gemma":[0.9971862,0.0007735723,0.0010464,0.0002217428,0.0001120214,0.0006599473],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.9619399,0.007445863,0.004727115,0.0004960808,0.001207946,0.00004704018,0.00008032127,0.000439758,0.005893559,0.00004481048,0.0002678645,0.01740981],"study_design_scores_gemma":[0.5941908,0.3779724,0.02228531,0.00005733206,0.001557659,0.000148614,0.000044432,0.0007173014,0.002075228,0.0001220376,0.0007928694,0.00003610591],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.995998,0.002841108,0.0001727759,0.0001081625,0.00005902769,0.0002948048,0.0002449929,0.00001462914,0.0002664419],"genre_scores_gemma":[0.996888,0.001128435,0.0003774553,0.0001756973,0.0001213908,0.0004425819,0.000432158,0.000006108909,0.0004281454],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003906226,"threshold_uncertainty_score":0.02065831,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.09954931507427511,"score_gpt":0.3482021834500605,"score_spread":0.2486528683757854,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}